Skip to main content
      RT @DrPetryna: #Abs1260 #acr22 @rheumnow #acrbest Clincial&US eval 54 RA &18 PsA pts: Tenderness aasoctd w/radio

      Olga Petryna DrPetryna

      3 years 10 months ago
      #Abs1260 #acr22 @rheumnow #acrbest Clincial&US eval 54 RA &18 PsA pts: Tenderness aasoctd w/radiographic progress in non-swollen jnts in PsA but not in RA. In tender non-swollen jnts in RA pts, baseline erosions& sonographic synovitis had significant impact on radio progression https://t.co/iqWvHiDeq8
      RT @uptoTate: RZB is efficacious in reducing signs and symptoms of PsA in patients, regardless of patterns of joint invo

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      RZB is efficacious in reducing signs and symptoms of PsA in patients, regardless of patterns of joint involvement Abs 1504 #ACR @AlexisOgdie @RheumNow https://t.co/AIEJbqrqBf https://t.co/kyiocs8TmL
      PreRA to Treat or Not!
      COVID Highlights
      RT @RichardPAConway: Herrán et al. Anti-vinculin abs in SSc. Single centre. Seen in 25%. Slow gastric transit (37% vs 2

      Richard Conway RichardPAConway

      3 years 10 months ago
      Herrán et al. Anti-vinculin abs in SSc. Single centre. Seen in 25%. Slow gastric transit (37% vs 21%). More LcSSc (OR 5), more thyroid disease (OR 3.2), less lung (OR 0.19). @RheumNow #ACR22 Abstr#1068 https://t.co/kPVgWPUl00 https://t.co/kmTERf78Ae
      RT @ericdeinmd: 13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22
      Obstetric domain redefined
      Added:
      ⭐️Cardiac thi

      Eric Dein ericdeinmd

      3 years 10 months ago
      13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22 Obstetric domain redefined Added: ⭐️Cardiac thickening/vegetation ⭐️Thrombocytopenia @Rheumnow https://t.co/Me2jrnvalU
      RT @Yuz6Yusof: Please read my short review on early experience/data pertaining to the use of #Evusheld in patients with

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 10 months ago
      Please read my short review on early experience/data pertaining to the use of #Evusheld in patients with rheumatic and musculoskeletal diseases presented at #ACR22 @RheumNow https://t.co/JA7WsWqMmz https://t.co/MRA0mQFIu8
      RT @KDAO2011: Uggh!
      What would you do if your pt gets pregnant while on MTX & loses her baby, are you liable for acc

      TheDaoIndex KDAO2011

      3 years 10 months ago
      Uggh! What would you do if your pt gets pregnant while on MTX & loses her baby, are you liable for accidental abortion? Should you advise termination if a pregnant pt’s health is deteriorating? @GreerDonley (#law professor) on theoretical risks #ACR22 @rheumnow https://t.co/L4FBWcKZnE
      RT @uptoTate: Delay in AS dx appeared to be BMI-dependent in female pts and both genders n PsA dx. In contrast to AS, SE

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      Delay in AS dx appeared to be BMI-dependent in female pts and both genders n PsA dx. In contrast to AS, SEC treatment response of early- and late-diagnosed PsA pts did not differ. Abs 1497 #ACR22 @RheumNow https://t.co/LBo3XapAT4 https://t.co/uAcfeiED4F
      RT @synovialjoints: Lower socioeconomic status (cluster 1) patients:
      ● older age at the diagnosis (37.9 vs. 32.6)
      ●

      Dr. Antoni Chan synovialjoints

      3 years 10 months ago
      Lower socioeconomic status (cluster 1) patients: ● older age at the diagnosis (37.9 vs. 32.6) ● longer diagnosis delay (7.8 vs. 6.8 years) ● higher BMI (27.6 vs. 25.9) ● greater structural damage vs cluster 2 Lopez-Medina C Abs0376 https://t.co/wXOksFGDKl #ACR22 @RheumNow https://t.co/1YVRA6r1sw
      RT @ericdeinmd: 13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22
      Novel Aspects
      Macrovascular Domains - Venous and A

      Eric Dein ericdeinmd

      3 years 10 months ago
      13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22 Novel Aspects Macrovascular Domains - Venous and Arterial by Low and High VTE, CVD risk profiles Microvasc - Suspected/Established @RheumNow https://t.co/M8NWRSyH4p
      RT @DrPetryna: #abs1235 #acr22 @rheumnow
      articular fibroblast activation in PSO assessed by 68Ga-FAPI-04 PET-CT assoctd

      Olga Petryna DrPetryna

      3 years 10 months ago
      #abs1235 #acr22 @rheumnow articular fibroblast activation in PSO assessed by 68Ga-FAPI-04 PET-CT assoctd w/⬆️ risk of developing PsA. 10 pts assessed: 6/7 pts (85.7%)w/ 68Ga-FAPI-04 uptake at synovio-entheseal sites progressed to PsA. median PsA-free time 207 (160-240)days https://t.co/Y6EHPaDwfh
      RT @uptoTate: PsA pts starting 1st DMARD tx, both early & late initiators experienced dz activity and PRO improvemen

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      PsA pts starting 1st DMARD tx, both early & late initiators experienced dz activity and PRO improvements up to 6 months post-initiation. Better response, including MDA, achieved in pts initiating DMARD tx w/in 1 yr of dx. Abs 1493 #ACRbest #ACR22 @RheumNow https://t.co/a94sZRQ3VF https://t.co/OSUEoChtFf
      ×